Active Ingredient History

  • Now
Vadastuximab talirine or SGN-CD33A is an antibody-drug conjugate or ADC directed to CD33 or Siglec-3 is a transmembrane receptor expressed on cells of myeloid lineage. The trial drug, being developed by Seattle Genetics and was in clinical trials for the treatment of acute myeloid leukemia (AML).   Wikipedia

More Chemistry
  • Mechanism of Action:
  • Multi-specific: No
  • Payload: pyrrolobenzodiazepine
  • Black Box: Missing data
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: Missing data
sgn-cd33a | vadastuximab talirine


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue